Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Technology appraisal guidance
Reference number: TA503
Published:
The appraisal of fulvestrant for untreated hormone-receptor positive metastatic breast cancer [ID951] has been rescheduled following an update on regulatory timings from the company. The first committee meeting will now take place on 08 August 2017.